Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice

被引:6
作者
Afouna, MI
Mehta, SC
Ghanem, AH
Higuchi, WI [1 ]
Kern, ER
DeClercq, E
El-Shattaway, HH
机构
[1] Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA
[2] Univ Utah, Dept Pharmaceut, Salt Lake City, UT 84112 USA
[3] Univ Utah, Dept Pharmaceut Chem, Salt Lake City, UT 84112 USA
[4] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
[5] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[6] Al Azhar Univ, Dept Pharmaceut, Nasr City, Cairo, Egypt
关键词
D O I
10.1021/js980406y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In recent studies we found that the topical effectiveness of acyclovir (ACV) formulations was a single-valued function of C*-the target site free drug concentration. The topical efficacy was the same when the therapy was initiated 0, 1, or 2 days after intracutaneous herpes simplex virus type-1 (HSV-1) inoculation in hairless mice. The purpose of the present study was to examine the hypothesis that the topical effectiveness of cidofovir (HPMPC) would not be a single valued function of C* and that it would be dependent upon when the therapy was initiated relative to the time of viral infection. Formulations of HPMPC and AGV in 95% DMSO as a vehicle were used. Hairless mice intracutaneously infected with HSV-1 were used, and 20 mu L of the test formulation was topically applied twice a day. In protocol A, the treatment was continued until the fourth day after virus inoculation, whereas in protocol B the treatment was terminated on the day of virus inoculation. Treatment was initiated on various days ranging from day -6 to day 4, and the lesions were scored on day 5. Treatment of ACV according to protocol A proved efficacious whether started as early as 6 days before virus inoculation or later, whereas the efficacy of ACV was annihilated if applied following protocol B. For HPMPC, on the other hand, the in vivo efficacies were found to be strongly dependent on how early the therapy was initiated, and significant efficacy was observed even when the treatment was terminated on the day of virus inoculation. This difference was attributed to the virus-independent intracellular phosphorylation of HPMPC and slow clearance of its metabolites from the cell. It was also noted that, similar to ACV, for HPMPC the topical efficacy is likely to be a function of C* for a fixed protocol. However, unlike for ACV, for HPMPC the efficacy was not a single-valued function of C*.
引用
收藏
页码:530 / 534
页数:5
相关论文
共 15 条
[1]  
ADUMA P, 1995, MOL PHARMACOL, V47, P816
[2]   Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2′-deoxyuridine and acyclovir formulations [J].
Afouna, MI ;
Mehta, SC ;
Ghanem, AH ;
Higuchi, WI ;
Kern, ER ;
De Clercq, E ;
El-Shattawy, HH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (08) :917-921
[3]   METABOLISM OF 1-(S)-(3-HYDROXY-2-PHOSPHONOMETHOXYPROPYL)-CYTOSINE (HPMPC) IN HUMAN EMBRYONIC LUNG-CELLS [J].
CIHLAR, T ;
VOTRUBA, I ;
HORSKA, K ;
LIBOSKA, R ;
ROSENBERG, I ;
HOLY, A .
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1992, 57 (03) :661-672
[4]   CLINICAL PHARMACOKINETICS OF CIDOFOVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS [J].
CUNDY, KC ;
PETTY, BG ;
FLAHERTY, J ;
FISHER, PE ;
POLIS, MA ;
WACHSMAN, M ;
LIETMAN, PS ;
LALEZARI, JP ;
HITCHCOCK, MJM ;
JAFFE, HS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1247-1252
[5]   EFFICACY OF (S)-1-(3-HYDROXY-2-PHOSPHONYLMETHOXYPROPYL)CYTOSINE IN VARIOUS MODELS OF HERPES-SIMPLEX VIRUS-INFECTION IN MICE [J].
DECLERCQ, E ;
HOLY, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :701-706
[6]   METABOLISM OF ACYCLOVIR IN VIRUS-INFECTED AND UNINFECTED CELLS [J].
FURMAN, PA ;
DEMIRANDA, P ;
STCLAIR, MH ;
ELION, GB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 20 (04) :518-524
[7]  
FYFE JA, 1978, J BIOL CHEM, V253, P8721
[8]   CONTROLLED (TRANS)DERMAL DELIVERY OF AN ANTIVIRAL AGENT (ACYCLOVIR) .1. AN INVIVO ANIMAL-MODEL FOR EFFICACY EVALUATION IN CUTANEOUS HSV-1 INFECTIONS [J].
GONSHO, A ;
IMANIDIS, G ;
VOGT, P ;
KERN, ER ;
TSUGE, H ;
SU, MH ;
CHOI, SH ;
HIGUCHI, WI .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 65 (03) :183-194
[9]   Cidofovir, a new agent with potent anti-herpesvirus activity [J].
Hitchcock, MJM ;
Jaffe, HS ;
Martin, JC ;
Stagg, RJ .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1996, 7 (03) :115-127
[10]  
HO HT, 1992, MOL PHARMACOL, V41, P197